The bioavailability problems posed by drug compounds with low aqueous solubility are made more challenging by the compounds' prevalence and by the accelerated timelines, limited availability of drug substance, and financial restrictions associated with many of today's drug-development programs. This presentation describes a proven model-based methodology used to select technologies to enhance the bioavailability of low-solubility molecules, as well as an integrated formulation approach to minimize first-in-human timelines. The role of API development and supply, solid-state characterization, and evaluation through in vitro testing will also be discussed. Case studies are presented for challenging compound classes. To learn more, please view our webinar.
Content Type: Webinar (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center